Vitality Watch

Dossier pubmed trial early 11-nov-2026
Small or early-phase human trial or pilot study

Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.

Key claim: The HABIT-GEMs trial evaluates whether the SGLT2 inhibitor henagliflozin is non-inferior to metformin XR in preserving appendicular skeletal muscle mass among older adults aged 60–85 with newly diagnosed type 2 diabetes.

Abstract

INTRODUCTION: Older adults with type 2 diabetes mellitus (T2DM) frequently present with sarcopenic obesity, characterised by excess adiposity and reduced skeletal muscle mass, which is associated with frailty, falls and increased mortality. Glycaemic control alone may be insufficient to address these concomitant changes in body composition, supporting the importance of therapies that preserve muscle mass while also limiting adverse changes in body composition. SGLT2 (sodium–glucose cotransporter 2) inhibitors induce weight loss, but their effects on fat and skeletal muscle mass remain incompletely understood, particularly in older adults. Metformin extended-release (metformin XR), a standard first-line therapy, is generally weight neutral and serves as an appropriate comparator. This non-inferiority randomised controlled trial is designed to compare the effects of henagliflozin and metformin XR on body composition in older adults with newly diagnosed T2DM. METHODS AND ANALYSIS: HABIT-GEMs is a multicentre, randomised, open-label and blinded-endpoint trial conducted in six tertiary hospitals in China. A total of 116 adults aged 60–85 years with newly diagnosed T2DM and elevated body fat will be randomised 1:1 to receive henagliflozin or metformin XR for 24 weeks. The primary outcome is the change in appendicular skeletal muscle mass index from baseline to week 24, assessed using multifrequency bioelectrical impedance analysis. Secondary outcomes include body composition, glycaemic indices, inflammatory markers, physical function and safety outcomes. ETHICS AND DISSEMINATION: The study has been approved by the Huadong Hospital Ethics Committee (2025K268) and will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent will be obtained from all participants. The trial is registered at ClinicalTrials.gov (NCT07323381) and the Chinese Clinical Trial Registry (ChiCTR2500112008). Results will be disseminated through peer-reviewed publications and scientific conferences. De-identified data may be shared upon reasonable request, subject to ethics approval. TRIAL REGISTRATION NUMBERS: NCT07323381 and ChiCTR2500112008.

Why this matters

[human-rct; protocol only] HABIT-GEMs places appendicular skeletal muscle mass preservation at the center of a randomized comparison of diabetes therapies in older adults, addressing a body-composition question relevant to sarcopenic obesity. [human-rct; protocol only] No outcomes are reported, so the protocol does not establish that either drug better preserves muscle or improves strength and physical function, and it provides no evidence about exercise protocols.

Source

Link

Briefing card

Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.
Stage: trial early · pubmed · 11-nov-2026

If you are aged 60–85 with newly diagnosed type 2 diabetes, this protocol reports no results yet on whether henagliflozin preserves muscle mass compared with metformin XR.

The HABIT-GEMs trial evaluates whether the SGLT2 inhibitor henagliflozin is non-inferior to metformin XR in preserving appendicular skeletal muscle mass among older adults aged 60–85 with newly diagnosed type 2 diabetes.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1136/bmjopen-2026-125545

build build 880 · 2bcef25 · 2026-11-18